Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead and Compugen enter exclusive license agreement for immunotherapy programme

December 20, 2023
Research and Development Gilead Sciences, Immunology, License Agreement, compugen, immunology

Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, …

News
markus-spiske-hvsr_cvecvi-unsplash

Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics

December 20, 2023
Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin

Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …

News

BioNTech achieves milestone at vaccine manufacturing site in Rwanda

December 19, 2023
Manufacturing and Production BioNTech, Immunology, manufacturing, rwanda

BioNTech has announced that it has reached the next milestone in the establishment of its mRNA vaccine manufacturing capacities in …

News

Elekta and BMS partner for digital treatment for melanoma

December 19, 2023
Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …

News

GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment

December 18, 2023
Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer

GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …

News

InnoCare shares results from phase 2 trial for atopic dermatitis treatment

December 18, 2023
Research and Development Dermatology, InnoCare, atopic dermatitis, clinical trial

InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met …

News

FDA approves Glaukos’ iDose TR treatment for glaucoma disease

December 15, 2023
Medical Communications FDA, Glaukos, Opthalmology, iDose TR, ocular hypertension, open-angle glaucoma

Glaukos Corporation has announced that the US Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for …

News

First patient dosed in Cullinan Oncology’s phase 1 trial for CLN-617

December 15, 2023
Research and Development Cullinan Oncology, Oncology, clinical trial, tumours

Cullinan Oncology has announced that the first patient has been dosed with CLN-617 in its phase 1 clinical trial, designed …

News

FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment

December 14, 2023
Medical Communications FDA, Mission Therapeutics, Nephrology, acute kidney injury, clinical trial

Mission Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application …

News

FDA grants Kyverna Therapeutics fast track designation for myasthenia gravis treatment

December 14, 2023
Medical Communications FDA, Kyverna Therapeutics, Musculo-skeletal disorder, myasthenia gravis

Kyverna Therapeutics has announced that it has gained fast track designation from the US Food and Drug Administration (FDA) for …

News

Merck and Moderna initiate phase 3 study of NSCLC treatment

December 13, 2023
Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial

Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 …

News
milad-fakurian-58z17lnvs4u-unsplash_2

PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research

December 13, 2023
Medical Communications Alzheimer's disease, Neurology, PharmaKure, UiTM

PharmaKure and the faculty of pharmacy at the University Teknologi MARA (UiTM), Malaysia, have announced a research collaboration focusing on …

News

EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma

December 12, 2023
Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma

Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …

News

AstraZeneca to acquire Icosavax for up to $1.1bn

December 12, 2023
Business Services AstraZeneca, Icosavax, Immunology, acquisition, immunology, vaccines

AstraZeneca has announced that it has entered into a definitive agreement to acquire Icosavax for approximately $15 per share or …

News

GSK’s Jemperli approved in EU as treatment for endometrial cancer

December 11, 2023
Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, …

News

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023
Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …

News

Regeneron shares data for multiple myeloma treatment

December 8, 2023
Medical Communications Cancer, Oncology, Regeneron, clinical trial

Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …

News

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023
Research and Development AI, Acceleration Consortium, Merck, Pharmacy, experimentation

Merck and the Acceleration Consortium have announced their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on …

News

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023
Business Services AbbVie, Cerevel Therapeutics, Neurology, acquisition

AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics for $45 per share, or …

News

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023
Research and Development NAYA Biosciences, NK cell therapies, ONK Therapeutics, Oncology, partnership

ONK Therapeutics and NAYA Biosciences have announced that they have entered into a research partnership to assess combination therapies consisting …

News

Latest content

AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC

May 31, 2024

Merck to acquire EyeBio for an upfront $1.3bn

May 31, 2024

Eli Lilly and UNICEF expand support for young people at risk of noncommunicable diseases

May 30, 2024

Full-Life Technologies’ IND application for prostate cancer cleared by FDA

May 30, 2024

Sanofi’s Sarclisa accepted for FDA priority review

May 29, 2024